Gibson Dunn Advises BVF Partners L.P. on up to $400 Million Financing for Immunic, Inc.
Tuesday, May 12, 2026 · first reported by Gibson Dunn
Gibson Dunn advised BVF Partners on up to $400M private placement financing for Immunic, a late-stage biotech.
- Firm
- BVF Partners
- Also named
- Gibson Dunn, Immunic, Inc.
- Asset class
- Venture
- Geography
- North America
In the directory
- Gibson Dunn · Legal counsel · fund lawyers at the firm
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 sourceMore in Venture capital
From the same day- S2G Investments Raises $1 Billion for First Fund As Independent FirmWSJ +4
- Kevin Hartz’s A* just closed its third fund with $450 millionTechCrunch
- Duration Ventures, Founded by Alumni of GC and Lightspeed, Aims for $375 Million FundWSJ
- Top Down Ventures Closes US$28M Founders Fund I, Exceeding Target – Company AnnouncementFinancial Times +3
- Kalos Ventures eyes workforce tech investments amid AI upheaval, closes $78.8m debut fundAltAssets
- Shuaa, Key Capital launch the region’s first venture capital secondaries fundEnterpriseAM